Target intelligence / Profile preview

UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase (MurD)

Target
MurD
Molecular classification
Enzyme, Ligase, Peptidoglycan biosynthetic enzyme
01

Overview

UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase (MurD) is a cytoplasmic enzyme in bacteria that catalyzes the ATP-dependent addition of D-glutamic acid to UDP-N-acetylmuramoyl-L-alanine, forming the dipeptide UDP-N-acetylmuramoyl-L-alanine-D-glutamate—a key step in peptidoglycan precursor synthesis for bacterial cell walls. MurD is one of four Mur ligases (MurC–F) performing the sequential assembly of the peptide stem, is structurally characterized by three conserved domains (binding UDP substrate, ATP, and the incoming amino acid), and is essential for bacterial survival, making it a prime target for novel antibiotic development. Multiple X-ray crystal structures of MurD have been solved, providing detailed insights into its mechanism and aiding structure-guided design of new antibacterial agents. Caveats/Limitations: - No clinical drugs on the market specifically target MurD; all cited inhibitors are investigational or tool compounds. - No standardized biomarkers or established safety issues due to lack of approved therapies, but selectivity and potential for resistance are major research concerns. - MurD is essential in bacteria but not present in eukaryotes, minimizing direct safety risks to humans.

Other names
MurDUDP-N-acetylmuramoyl-L-alanine:D-glutamate ligaseMuramyl ligase DUDP-MurNAc-L-Ala:D-Glu ligase
02

Mechanism of action

Competitive inhibition of substrate binding site (most designed inhibitors) ATPase inhibition (by blocking ATP-binding domain)

03

Biological functions

Peptidoglycan biosynthesisCell wall synthesis (bacteria)Essential for bacterial cell viability
04

Disease associations

Infection (bacterial, as it is essential for bacterial survival and absence in eukaryotes makes it a key antibacterial target)
05

Safety considerations

Selectivity and resistance: Designing MurD inhibitors with selectivity for bacterial enzymes and without off-target effects in humans; resistance could develop in treated bacteriaNo standardized biomarkers or established safety issues due to lack of approved therapies, but selectivity and potential for resistance are major research concernsMurD is essential in bacteria but not present in eukaryotes, minimizing direct safety risks to humans
06

Interacting drugs

Various MurD inhibitors (including aminothiazole class), several experimental inhibitors in antibacterial drug development

1 more in the full profile.

Beyond the preview

Go deeper on UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase (MurD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase (MurD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call